Clinical and Genetic Features of Brainstem Glioma in Adults: A Report of 50 Cases in a Single Center

Chunhui Zhou; Hao Zhao; Fan Yang; Luokai Huangfu; Chao Dong; Shuwei Wang; Jianning Zhang

추천

검색

자료유형: 학술저널

저자정보: Chunhui Zhou (The Sixth Medical Center of PLA General Hospital) Hao Zhao (The Sixth Medical Center of PLA General Hospital) Fan Yang (The Sixth Medical Center of PLA General Hospital) Luokai Huangfu (The Sixth Medical Center of PLA General Hospital) Chao Dong (The Sixth Medical Center of PLA General Hospital) Shuwei Wang (The Sixth Medical Center of PLA General Hospital) Jianning Zhang (The Sixth Medical Center of PLA General Hospital)

저널정보: 대한신경과학회 Journal of Clinical Neurology Journal of Clinical Neurology 제17권 제2호

발행연도: 2021.1

수록면: 220 - 228 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background and Purpose Brainstem gliomas (BSGs) in adults are rare brain tumors with dismal outcomes. The aim of this study was to determine the clinical and genetic features in a series of BSGs and their association with the prognosis. Methods Fifty patients who underwent a stereotactic biopsy between January 2016 and April 2018 at a single institution were collected. Data on clinicopathological characteristics were analyzed and factors associated with patient survival were identified using a Cox regression model. Results The median age at diagnosis was 55.5 years, and 62% of the patients were male. Glioblastoma (44%) accounted for the largest proportion of BSGs, and oligodendroglioma (2 of 50) was rarely encountered. The IDH mutation (6 of 44) occurred infrequently in astrocytomas, and IDH-mutant tumors harbored both ATRX loss and MGMT promoter methylation at a relatively low level. Wild-type IDH astrocytomas were identified as having high rates of 1p/19q codeletion (5 of 38) and loss of heterozygosity 1p (8 of 38) or 19q (8 of 38) only. In diffuse midline glioma H3K27M mutant, MGMT promoter methylation occurred in three of four cases. Patients were offered radiotherapy and/or concurrent/adjuvant temozolomide chemotherapy, and their median survival time was 13 months. Multivariate analysis revealed that a low tumor grade, absence of tumor enhancement, duration of symptoms ≥3 months, Karnofsky performance status ≥70, and ATRX loss conferred a survival advantage. Conclusions Adult BSGs showed different molecular genetic characteristics, but also resembled supratentorial gliomas in their clinical features associated with oncological outcomes.

#brain stem neoplasms #glioma #molecular epidemiology #prognosis.

참고문헌 (34)

참고문헌 신청

Ostrom QT / 2017 / CBTRUS Statistical Report : primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014 / Neuro Oncol 19:v1

Khalid SI / 2019 / Pediatric Brainstem gliomas : a retrospective study of 180 patients from the SEER database / Pediatr Neurosurg 54:151~164

Eisele SC / 2016 / Adult brainstem gliomas / Cancer 122:2799~2809

Guillamo JS / 2001 / Brainstem gliomas in adults : prognostic factors and classification / Brain 124:2528~2539

Landolfi JC / 1998 / Adult brainstem gliomas / Neurology 51:1136~1139

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!